glp-1 receptor agonists in idiopathic intracranial hypertension Treatment with is associated with significant weight loss and favorable headache outcomes | The Journal of Headache and Pain GLP-1 receptor agonists may improve

The cardiovascular benefits, including reductions in MACE and stroke, also accumulate over time, with the most substantial gains observed within the first 24 to 36 months of treatment [124, 125]

The Science Behind Dual Agonist Design Creating tirzepatide required sophisticated pharmaceutical engineering to activate both receptors effectively

Sustainability Concerns : The requirement for potentially lifelong therapy, combined with rapid weight regain upon discontinuation, raises questions about long-term sustainability and practical implementation

4), which did not withstand the adjustment for weight loss (Supplementary Table 2)

Preclinical studies have shown that large doses of GLP-1RAs can reduce lipid deposition and plaque volume on the aortic surface of hyperglycemic mice via an AMPK-independent action in streptozotocin (STZ)-induced hyperglycemic and hyperlipidemic mice or type 1 diabetic rats [55]